We further characterized the role of the lipid metabolic enzyme LPCAT1 in ESCC tumor growth and poor patient outcome and posit that LPCAT1 is a potential target for esophageal cancer diagnosis and treatment. This evidence concerns the gene LPCAT1 and esophageal cancer.